Skip to main content
TipRanks
Go Ultimate75% OFF

Viyash Scientific (VIYASH) AI Stock Analysis

4 Followers
IN:VIYASH

Viyash Scientific

(NSE:VIYASH)

Select Model
Rating:57Neutral
Price Target:INR 245.00▲(3.70% Upside)
Action:reiterated
Date:08/21/26

The overall score reflects a company with an improving but still transitional financial profile, where the FY2026 rebound in revenue, margins, and cash generation is offset by a volatile earnings history and uneven cash flow quality. Technicals modestly enhance the score, with price action above key moving averages but only neutral momentum and higher beta-driven volatility. A rich P/E multiple without supporting dividend yield data weighs on the final score, indicating that the stock’s valuation is ahead of its demonstrated consistency, keeping the rating in the mid-range rather than at a premium level.

Positive Factors
Revenue AccelerationThe sharp 2026 revenue acceleration indicates substantially stronger commercial traction and expanding business activity. If this growth persists beyond the rebound period, it can improve operating leverage, support reinvestment, and strengthen the company’s competitive position over the next several quarters.
Negative Factors
Earnings VolatilityThe history of losses and uneven margins shows that recent profitability has not yet been proven across a full operating cycle. Continued earnings volatility could make results less predictable, weaken confidence in sustainable margins, and limit the reliability of future profit growth.

Viyash Scientific (VIYASH) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%IN:VIYASH-6.23%INDA-5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 112.69B
Dividend Yield
―
Average Volume (3M)
370.64K
Price to Earnings (P/E)
61.8
Beta (1Y)
1.09
Revenue Growth
96.48%
EPS Growth
251.87%
Country
India
Employees
1,244
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Viyash Scientific Business Overview & Revenue Model

Company Description

Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, incl...

Viyash Scientific Financial Statement Overview

Summary

Financial performance is moderately strong, reflecting a clear FY2026 turnaround in revenue, margins, and cash generation, but constrained by volatile past results, a prior loss, uneven returns, and still-improving cash flow quality.

Income Statement

58Neutral

Balance Sheet

66Positive

Cash Flow

54Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue31.49B34.20B15.51B13.66B14.18B14.10B
Gross Profit10.67B10.58B7.40B5.53B1.59B5.66B
EBITDA5.84B6.54B1.59B549.80M-464.48M1.18B
Net Income1.71B1.77B218.80M-358.69M-1.21B409.55M
Balance Sheet
Total Assets046.28B16.02B15.40B15.29B14.51B
Cash, Cash Equivalents and Short-Term Investments2.59B2.70B632.04M687.85M416.25M591.21M
Total Debt04.90B4.81B4.88B4.44B3.65B
Total Liabilities-31.15B15.14B8.32B8.27B7.80B7.11B
Stockholders Equity31.15B29.11B7.04B6.57B6.99B6.92B
Cash Flow
Free Cash Flow288.00M1.29B442.70M-2.12M-693.71M-18.69M
Operating Cash Flow449.00M2.64B833.60M305.95M168.08M305.95M
Investing Cash Flow-42.20M-938.90M-247.80M-119.05M-649.58M-955.66M
Financing Cash Flow-325.70M-543.10M-607.30M45.46M322.28M672.57M

Viyash Scientific Technical Analysis

Technical Analysis SentimentPositive
Last Price236.25

Price Trends

50DMA238.57Positive
100DMA253.80Positive
200DMA235.22Positive

Market Momentum

MACD3.48Negative
RSI66.08Neutral
STOCH90.55Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIYASH, the sentiment is Positive. The current price of 236.25 is above the 20-day moving average (MA) of 226.15, below the 50-day MA of 238.57, and above the 200-day MA of 235.22, indicating a bullish trend. The MACD of 3.48 indicates Negative momentum. The RSI at 66.08 is Neutral, neither overbought nor oversold. The STOCH value of 90.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIYASH.

Viyash Scientific Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:VIYASH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:CAPLIPOINTIN:CAPLIPOINT85OutperformINR 181.40B26.20―0.34%16.84%17.02%
IN:STARIN:STAR77OutperformINR 93.51B15.07―0.49%11.28%55.18%
IN:ALIVUSIN:ALIVUS76OutperformINR 179.46B26.84―0.34%8.19%26.12%
IN:AKUMSIN:AKUMS73OutperformINR 116.56B31.21―0.40%17.50%14.74%
IN:APLLTDIN:APLLTD71OutperformINR 202.40B24.00―1.16%19.68%33.03%
IN:VIYASHIN:VIYASH57NeutralINR 112.65B61.79――96.48%251.87%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

-25%0%25%50%75%IN:VIYASHIN:AKUMSIN:APLLTDIN:CAPLIPOINTIN:ALIVUSIN:STARDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:VIYASH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:VIYASHViyash Scientific Limited236.25-11.40-4.60%
IN:AKUMSAkums Drugs and Pharmaceuticals Limited722.20293.7368.55%
IN:APLLTDAlembic Pharmaceuticals Limited1055.80155.7917.31%
IN:CAPLIPOINTCaplin Point Laboratories Limited2344.45436.9322.91%
IN:ALIVUSGlenmark Life Sciences Limited1448.50530.2857.75%
IN:STARStrides Pharma Science Ltd986.0024.752.57%

Viyash Scientific Corporate Events

Viyash Reports H1 FY27 Revenue and PAT Growth

Nov 13, 2026

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is an integrated pharmaceutical company operating in formulations, APIs and CDMO services. Its businesses serve human and animal health markets.For the quarter and half year end...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026